

Research Oversight Process

# Annual Update on Approved Data Access

Period covered: 1st January 2025 - 31st December 2025

**Data access request updates due during this period:**

| <i>Applicant</i>                       | <i>Date access approved</i> | <i>Annual update due</i> | <i>Page</i>       |
|--|-----------------------------|--------------------------|-------------------|
| <b>Roche</b>                           | November 2023               | November 2025            | <a href="#">3</a> |
| <b>Pfizer</b>                          | December 2023               | December 2025            | <a href="#">4</a> |
| <b>Gilead</b>                          | June 2024                   | June 2025                | <a href="#">5</a> |
| <b>Takeda</b>                          | June 2024                   | June 2025                | <a href="#">6</a> |
| <b>Novartis</b>                        | December 2024               | December 2025            | <a href="#">7</a> |
| <b>Flatiron (on behalf of J&amp;J)</b> | December 2024               | December 2025            | <a href="#">8</a> |
| <b>LSHTM</b>                           | December 2024               | December 2025            | <a href="#">9</a> |

Please see the [data access register](#) to view all meeting summaries.

# ROCHE

|                          |  |
|--------------------------|--|
| TARGET DISEASES          | <ul style="list-style-type: none"> <li>■ Multiple myeloma</li> <li>■ Diffuse large B-cell lymphoma</li> <li>■ Chronic lymphatic leukemia</li> <li>■ Prostate cancer</li> <li>■ Breast cancer</li> <li>■ Non-small cell lung cancer</li> <li>■ Colorectal cancer</li> <li>■ Small cell lung cancer</li> </ul> |
| INTENDED USE CASES       | <ul style="list-style-type: none"> <li>■ Clinical trial design and feasibility</li> <li>■ Health technology assessment, health economics outcomes research, and Market access</li> <li>■ Understanding and monitoring the treatment landscape</li> </ul>   |
| DATE OF REQUEST APPROVAL | <p>30th November 2023</p> <p>20th September 2024 (<i>addition of colorectal cancer and small cell lung cancer datasets, with no changes to intended use cases</i>)</p>   |

## Annual Update

*Period covered: 1st December 2024 - 30th November 2025*

|                      | Research Title   | Summary of Research Impact |
|----------------------|--|----------------------------|
| CONFERENCE ABSTRACTS | <ul style="list-style-type: none"> <li>■ None</li> </ul> | --                         |
| PUBLICATIONS         | <ul style="list-style-type: none"> <li>■ None</li> </ul> | --                         |
| OTHER                | <ul style="list-style-type: none"> <li>■ None</li> </ul> | --                         |

# PFIZER

|                          |   |
|--------------------------|---|
| TARGET DISEASES          | <ul style="list-style-type: none"> <li>■ Breast cancer</li> </ul>   |
| INTENDED USE CASES       | <ul style="list-style-type: none"> <li>■ Product Development and Portfolio Strategy</li> <li>■ Clinical Trial Design and Feasibility</li> <li>■ Supporting Regulatory Submissions</li> <li>■ Product Launch Planning</li> <li>■ Health Technology Assessment, Health Economics Outcomes Research and Market Access</li> <li>■ Label / Indication Expansion</li> <li>■ Understanding and Monitoring Treatment Landscape</li> </ul> |
| DATE OF REQUEST APPROVAL | 14th December, 2023   |

## Annual Update

*Period covered: 15th December 2024 - 14th December 2025*

|                      | Research Title   | Summary of Research Impact |
|----------------------|--|----------------------------|
| CONFERENCE ABSTRACTS | <ul style="list-style-type: none"> <li>■ None</li> </ul> | --                         |
| PUBLICATIONS         | <ul style="list-style-type: none"> <li>■ None</li> </ul> | --                         |
| OTHER                | <ul style="list-style-type: none"> <li>■ None</li> </ul> | --                         |

# GILEAD

|                          |   |
|--------------------------|---|
| TARGET DISEASES          | <ul style="list-style-type: none"> <li>■ Breast cancer</li> </ul>   |
| INTENDED USE CASES       | <ul style="list-style-type: none"> <li>■ Product launch planning</li> <li>■ Health Technology Assessment (HTA)</li> <li>■ Health Economics Outcomes Research (HEOR) and Market Access,</li> <li>■ Understanding and monitoring treatment landscape</li> </ul> |
| DATE OF REQUEST APPROVAL | 4th June 2024   |

## Annual Update

*Period covered: 5th June 2024 - 4th June 2025*

|                      | Research Title  | Summary of Research Impact   |
|----------------------|---|--|
| CONFERENCE ABSTRACTS | <ul style="list-style-type: none"> <li>■ ISPOR 2025: Real-World Study of Breast Cancer Epidemiology and Treatment Patterns in the United Kingdom: A Pilot Study to Assess the Flatiron Health Research Database in the United Kingdom.</li> </ul> | The findings validate Flatiron’s UK dataset as a clinically reliable source of real-world evidence, strengthening its utility for Gilead’s breast cancer research and future oncology use cases. |
| PUBLICATIONS         | <ul style="list-style-type: none"> <li>■ None</li> </ul>  | --   |
| OTHER                | <ul style="list-style-type: none"> <li>■ None</li> </ul>  | --   |

# TAKEDA

|                          |  |
|--------------------------|--|
| TARGET DISEASES          | <ul style="list-style-type: none"> <li>■ Colorectal Cancer</li> </ul>  |
| INTENDED USE CASES       | <ul style="list-style-type: none"> <li>■ Health Technology Assessment (HTA)</li> <li>■ Health Economics Outcomes Research (HEOR) and Market Access,</li> <li>■ Understanding and monitoring treatment landscape</li> </ul> |
| DATE OF REQUEST APPROVAL | 4th June 2024  |

## Annual Update

*Period covered: 5th June 2024 - 4th June 2025*

|                      | Research Title   | Summary of Research Impact |
|----------------------|--|----------------------------|
| CONFERENCE ABSTRACTS | <ul style="list-style-type: none"> <li>■ None</li> </ul> | --                         |
| PUBLICATIONS         | <ul style="list-style-type: none"> <li>■ None</li> </ul> | --                         |
| OTHER                | <ul style="list-style-type: none"> <li>■ None</li> </ul> | --                         |

# NOVARTIS

|                          |  |
|--------------------------|--|
| TARGET DISEASES          | <ul style="list-style-type: none"> <li>■ Prostate Cancer</li> </ul>  |
| INTENDED USE CASES       | <ul style="list-style-type: none"> <li>■ Product Development and Portfolio Strategy</li> <li>■ Clinical Trial Design and Feasibility</li> <li>■ Supporting Regulatory Submissions</li> <li>■ Health Technology Assessment, Health Economics Outcomes Research and Market Access</li> <li>■ Understanding and Monitoring Treatment Landscape</li> </ul> |
| DATE OF REQUEST APPROVAL | 3rd December 2024  |

## Annual Update

*Period covered: 4th December 2024 - 3rd December 2025*

|                      | Research Title   | Summary of Research Impact |
|----------------------|--|----------------------------|
| CONFERENCE ABSTRACTS | <ul style="list-style-type: none"> <li>■ None</li> </ul> | --                         |
| PUBLICATIONS         | <ul style="list-style-type: none"> <li>■ None</li> </ul> | --                         |
| OTHER                | <ul style="list-style-type: none"> <li>■ None</li> </ul> | --                         |

## FLATIRON (ON BEHALF OF J&J)

|                          |                              |
|--------------------------|------------------------------|
| TARGET DISEASES          | ■ Lung Cancer                |
| INTENDED USE CASES       | ■ Fit-for-purpose assessment |
| DATE OF REQUEST APPROVAL | 3rd December 2024            |

### Annual Update

*Period covered: 4th December 2024 - 3rd December 2025*

|                      | Research Title                                | Summary of Research Impact   |
|----------------------|---|--|
| CONFERENCE ABSTRACTS | ■ None  | --   |
| PUBLICATIONS         | ■ None  | --   |
| OTHER                | ■ J&J will be doing a refresh of the analyses | Refreshing the analysis provides J&J the opportunity to further understand the current treatment patterns and highlight areas of unmet needs for lung cancer patients. In the future, should J&J decide to opt for full access to the data, they could use the data to refine their development processes in order to ensure better treatment options for patients with lung cancer. |

# LSHTM

|                          |                     |
|--------------------------|---------------------|
| TARGET DISEASES          | ■ Breast cancer     |
| INTENDED USE CASES       | ■ Academic Research |
| DATE OF REQUEST APPROVAL | 10th December 2024  |

## Annual Update

*Period covered: 11th December 2024 - 10th December 2025*

|                      | Research Title                 | Summary of Research Impact |
|----------------------|--------------------------------|----------------------------|
| CONFERENCE ABSTRACTS | ■ N/A                          | --                         |
| PUBLICATIONS         | ■ N/A                          | --                         |
| OTHER                | ■ The project did not go ahead | --                         |